Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC006 in Advanced Solid Tumors
NCT06304571Phase 1Recruiting
- Start
- Feb 2024
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HC006 in solid tumor (advanced stage) (2 arms). Primary endpoints: Dose Limiting Toxicities up to 24 months, Adverse Events up to 24 months and 2 more. Started Feb 2024; status: recruiting.
02
Drugs
HC006
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06304571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304571.